[go: up one dir, main page]

MA27999A1 - Inhibiteurs de caspases contenant un cycle isoxazolinique - Google Patents

Inhibiteurs de caspases contenant un cycle isoxazolinique

Info

Publication number
MA27999A1
MA27999A1 MA28820A MA28820A MA27999A1 MA 27999 A1 MA27999 A1 MA 27999A1 MA 28820 A MA28820 A MA 28820A MA 28820 A MA28820 A MA 28820A MA 27999 A1 MA27999 A1 MA 27999A1
Authority
MA
Morocco
Prior art keywords
isoxazolinic
caspases
inhibitors
cycle
derivative
Prior art date
Application number
MA28820A
Other languages
English (en)
Inventor
Hye-Kyung Chang
Yeong-Soo Oh
Cheol-Won Park
Yong-Jin Jang
Tae-Kyo Park
Sung-Sub Kim
Min-Jung Kim
Mi-Jeong Park
Jung-Gyu Park
Hee-Dong Park
Kyeong-Sik Min
Tae-Soo Lee
Sang-Kyun Lee
Soo-Hyeon Kim
Hee-Kyung Jeong
Sun-Hwa Lee
Hwa-Dong Kim
Ae-Ri Kim
Ki-Sook Park
Hyun-Ik Shin
Hyeong-Wook Choi
Kyu-Woong Lee
Jae-Hoon Lee
Tae-Ho Heo
Ho-Jun Kim
Tae-Sik Kwon
Original Assignee
Hyeong-Wook Choi
Kyu-Woong Lee
Jae-Hoon Lee
Tae-Ho Heo
Ho-Jun Kim
Tae-Sik Kwon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyeong-Wook Choi, Kyu-Woong Lee, Jae-Hoon Lee, Tae-Ho Heo, Ho-Jun Kim, Tae-Sik Kwon filed Critical Hyeong-Wook Choi
Publication of MA27999A1 publication Critical patent/MA27999A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne un dérivé isoxazolinique constituant un inhibiteur de diverses caspases, un procédé de préparation de ce dérivé et une composition thérapeutique destinée à prévenir l'inflammation et l'apoptose, cette composition comprenant ledit dérivé.
MA28820A 2003-08-27 2006-02-17 Inhibiteurs de caspases contenant un cycle isoxazolinique MA27999A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20030059451 2003-08-27

Publications (1)

Publication Number Publication Date
MA27999A1 true MA27999A1 (fr) 2006-07-03

Family

ID=36102769

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28820A MA27999A1 (fr) 2003-08-27 2006-02-17 Inhibiteurs de caspases contenant un cycle isoxazolinique

Country Status (26)

Country Link
US (1) US7557133B2 (fr)
EP (1) EP1660464B1 (fr)
JP (1) JP4503017B2 (fr)
KR (1) KR100594544B1 (fr)
CN (1) CN1842521B (fr)
AP (1) AP2104A (fr)
AR (1) AR045503A1 (fr)
BR (1) BRPI0413848B8 (fr)
CA (1) CA2535711C (fr)
EA (1) EA012080B1 (fr)
EC (1) ECSP066378A (fr)
EG (1) EG25751A (fr)
IL (1) IL173638A (fr)
MA (1) MA27999A1 (fr)
MX (1) MXPA06002267A (fr)
MY (1) MY162110A (fr)
NO (1) NO335620B1 (fr)
NZ (1) NZ545216A (fr)
OA (1) OA13244A (fr)
PE (1) PE20050371A1 (fr)
TR (1) TR200600899T2 (fr)
TW (1) TWI346110B (fr)
UA (1) UA83240C2 (fr)
UY (1) UY28494A1 (fr)
WO (1) WO2005021516A1 (fr)
ZA (1) ZA200601586B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100774999B1 (ko) 2005-02-26 2007-11-09 주식회사 엘지생명과학 이소옥사졸린 유도체 및 그의 제조 방법
US7754909B1 (en) * 2005-04-06 2010-07-13 The Florida State University Research Foundation, Inc. Compounds and methods of arylmethylation (benzylation) as protection for alcohol groups during chemical synthesis
KR101299720B1 (ko) * 2006-08-16 2013-08-28 주식회사 엘지생명과학 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법
KR20080042290A (ko) * 2006-11-09 2008-05-15 주식회사 엘지생명과학 피리돈 구조를 포함하는 캐스파제 저해제
EP2186804B1 (fr) * 2007-08-10 2015-06-17 Nippon Soda Co., Ltd. Composé hétérocyclique contenant de l'azote et agent de lutte contre les animaux nuisibles
KR20090099886A (ko) * 2008-03-18 2009-09-23 주식회사 엘지생명과학 캐스파제 저해제의 프로드럭
EP2288615B1 (fr) 2008-05-21 2017-06-21 Genesis Technologies Limited Inhibiteurs sélectifs de caspase et leurs utilisations
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012130798A1 (fr) 2011-03-31 2012-10-04 Bayer Cropscience Ag 3-phénylisoxazolino-5-carboxamides et 3-phénylisoxazolino-5-thioamides à activité herbicide et fongicide
WO2012140500A1 (fr) 2011-04-15 2012-10-18 New World Laboratories, Inc. Inhibiteurs sélectifs de cystéine protéase et leurs utilisations
BR112015006560A2 (pt) * 2012-09-25 2017-07-04 Bayer Cropscience Ag 3-heteroaril-isoxazolina-5-carboxamidas e 3-heteroaril-isoxazolina-5-tioamidas com atividade herbicida e fungicida
US9516880B2 (en) * 2012-09-25 2016-12-13 Bayer Cropscience Ag Herbicidal and fungicidal 5-oxy-substituted 3-phenylisoxazoline-5-carboxamides and 5-oxy-substituted 3-phenylisoxazoline-5-thioamides
KR101977920B1 (ko) 2012-09-25 2019-05-13 바이엘 크롭사이언스 악티엔게젤샤프트 제초 작용을 가지는 3-페닐이속사졸린 유도체
JP2017095353A (ja) * 2014-03-27 2017-06-01 日本曹達株式会社 イソオキサゾリン−５−カルボキサミド化合物および有害生物防除剤
AU2015259471A1 (en) 2014-05-12 2016-11-24 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with caspase inhibitors
CN105753853B (zh) 2014-12-16 2020-08-04 沈阳中化农药化工研发有限公司 一种含异恶唑啉的脲嘧啶类化合物及其用途
WO2017079566A1 (fr) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Inhibiteurs de caspase destinés à être utilisés dans le traitement du cancer
US20190022043A1 (en) 2015-12-31 2019-01-24 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
MX2019003889A (es) 2016-10-05 2019-08-12 Novartis Ag Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
TWI764977B (zh) * 2017-01-23 2022-05-21 大陸商正大天晴藥業集團股份有限公司 作爲ｃａｓｐａｓｅ抑制劑的聯環化合物、含有其的藥物組合物及其應用
PL3638665T3 (pl) 2017-06-13 2021-12-27 Bayer Aktiengesellschaft Chwastobójczo skuteczne 3-fenyloizoksazolino-5-karboksyamidy kwasów i estrów tetrahydro- i dihydrofuranokarboksylowych
CN110799511B (zh) 2017-06-13 2023-09-01 拜耳公司 除草活性的四氢和二氢呋喃甲酰胺的3-苯基异噁唑啉-5-甲酰胺
US20200369630A1 (en) 2017-08-17 2020-11-26 Bayer Aktiengesellschaft Herbicidally active 3-phenyl-5-trifluoromethylisoxazoline-5-carboxamides of cyclopentylcarboxylic acids and esters
DK3743411T3 (da) 2018-01-25 2023-02-13 Bayer Ag Herbicidt virksomt 3-phenylisoxazolin-5-carboxamider af cyclopentenylcarbonsyrederivater
US12185723B2 (en) 2019-03-12 2025-01-07 Bayer Aktiengesellschaft Herbicidally active 3-phenylisoxazoline-5-carboxamides of s-containing cyclopentenylcarboxylic esters
KR102437095B1 (ko) * 2019-04-19 2022-08-26 주식회사 엘지화학 캐스파제 저해제의 프로드럭
KR102442103B1 (ko) * 2019-04-30 2022-09-08 주식회사 엘지화학 캐스파제 저해제의 프로드럭
KR102366226B1 (ko) * 2019-05-31 2022-02-22 주식회사 엘지화학 캐스파제 저해제 프로드럭을 함유하는 주사용 조성물 및 이의 제조 방법
EP4242213A4 (fr) 2020-12-10 2024-05-08 Lg Chem, Ltd. Composé d'acide borique
WO2022123062A1 (fr) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocage de la caspase et/ou de la fasl pour prévenir une issue fatale chez des patients atteints de la covid-19
CN114908028B (zh) * 2022-04-19 2024-05-31 杭州师范大学 一种双相体系下化学酶法级联催化腈类化合物的一锅法合成工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2738486B2 (ja) * 1992-11-20 1998-04-08 ファイザー製薬株式会社 抗炎症剤としての新規なイソオキサゾリン類
PT730587E (pt) * 1993-11-26 2000-05-31 Pfizer 3-aril-2-isoxazolinas como agentes anti-inflamatorios
ES2104424T3 (es) * 1993-11-26 1997-10-01 Pfizer Compuestos de isoxazolina como agentes antiinflamatorios.
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
KR100373375B1 (ko) * 1998-04-03 2003-06-12 주식회사 엘지생명과학 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제
AU5762899A (en) * 1999-09-17 2001-04-24 Lg Chemical Ltd. Caspase inhibitor
ATE273705T1 (de) * 1999-09-17 2004-09-15 Lg Chem Investment Ltd Caspase-hemmer

Also Published As

Publication number Publication date
AR045503A1 (es) 2005-11-02
OA13244A (en) 2007-01-31
ECSP066378A (es) 2006-08-30
TR200600899T2 (tr) 2006-09-21
IL173638A0 (en) 2006-07-05
UY28494A1 (es) 2005-02-28
MY162110A (en) 2017-05-31
CN1842521B (zh) 2012-09-05
BRPI0413848A (pt) 2006-10-24
BRPI0413848B8 (pt) 2021-05-25
EP1660464B1 (fr) 2015-02-25
EA200600465A1 (ru) 2006-08-25
CA2535711A1 (fr) 2005-03-10
MXPA06002267A (es) 2006-05-17
KR100594544B1 (ko) 2006-06-30
TWI346110B (en) 2011-08-01
AP2006003509A0 (en) 2006-02-28
NO20061362L (no) 2006-03-24
UA83240C2 (ru) 2008-06-25
ZA200601586B (en) 2007-05-30
BRPI0413848B1 (pt) 2019-04-30
JP4503017B2 (ja) 2010-07-14
EA012080B1 (ru) 2009-08-28
AP2104A (en) 2010-02-06
US7557133B2 (en) 2009-07-07
PE20050371A1 (es) 2005-08-17
HK1092788A1 (en) 2007-02-16
EG25751A (en) 2012-06-25
WO2005021516A1 (fr) 2005-03-10
AU2004268895A1 (en) 2005-03-10
CA2535711C (fr) 2011-07-05
JP2007503429A (ja) 2007-02-22
NO335620B1 (no) 2015-01-12
KR20050022364A (ko) 2005-03-07
EP1660464A4 (fr) 2008-11-26
IL173638A (en) 2011-12-29
CN1842521A (zh) 2006-10-04
EP1660464A1 (fr) 2006-05-31
NZ545216A (en) 2009-06-26
US20060223848A1 (en) 2006-10-05
TW200512199A (en) 2005-04-01

Similar Documents

Publication Publication Date Title
MA27999A1 (fr) Inhibiteurs de caspases contenant un cycle isoxazolinique
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
EP1554256A4 (fr) Inhibiteurs de piperidino pyrimidine dipeptidyl peptidase utilises dans le traitement du diabete
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
ATE401314T1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
DK1257550T3 (da) Blodplade-ADP-receptor-inhibitor
ECSP055525A (es) Inhibidores de cinasas de tirosina
ATE297203T1 (de) Antithrombotische mitteln
ATE437872T1 (de) Proteinkinaseinhibitoren
EP1385508A4 (fr) Inhibiteurs de peptidase dipeptidyl destines au traitement ou a la prevention du diabete
MA27556A1 (fr) Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
ATE478664T1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
ATE489089T1 (de) Azole als malonyl-coa decarboxylase hemmer verwendbar als modulatoren des metabolismus
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
SE9801494D0 (sv) Novel use
DE60329326D1 (de) Tace inhibitoren